Outcome of patients with recurrent/metastatic squamous cell head and neck cancer treated with platinum‑based chemotherapy with or without cetuximab in real‑world practice

Zupančič,Tina; Zakotnik,Branko; Kuhar,Cvetka Grašič

doi:10.3892/mco.2021.2352

Outcome of patients with recurrent/metastatic squamous cell head and neck cancer treated with platinum‑based chemotherapy with or without cetuximab in real‑world practice

Authors:
- Tina Zupančič
- Branko Zakotnik
- Cvetka Grašič Kuhar
View Affiliations

Affiliations: Department of Medical Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia
Published online on: July 15, 2021 https://doi.org/10.3892/mco.2021.2352
Article Number: 190

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with recurrent or metastatic squamous cell head and neck cancer (R/M SCHNC) exhibit a poor prognosis with a median overall survival (OS) time of <1 year. Platinum‑based chemotherapy with or without cetuximab has been the standard of care in the last decade. The aim of the current retrospective study was to evaluate the outcome and tolerability of treatment in patients with R/M SCHNC receiving platinum/5‑fluorouracil/cetuximab (PFE) chemotherapy compared with platinum/5‑fluorouracil (PF) chemotherapy in daily clinical practice. A retrospective analysis was performed using the data of patients treated at the Institute of Oncology Ljubljana between April 2008 and May 2018. Progression‑free survival (PFS) and OS were calculated with the Kaplan‑Meier method and compared with the log‑rank test. Multivariate regression Cox analysis was used to determine independent prognostic factors. A total of 67 patients were treated at the aforementioned Institute: 34 patients received the PF and 33 the PFE regimen. The mean age of patients was 54.6 years and 91% of patients were male. Median PFS time was 6.6 vs. 7.1 months for the PF vs. PFE groups, respectively (P=0.852). Median OS time was 9.6 vs. 11.5 months for the PF vs. PFE groups, respectively (P=0.029). The prognostic factor for PFS was partial remission [hazard ratio (HR), 0.32; 95% CI, 0.15‑0.70; P=0.004]. Prognostic factors for OS were partial remission (HR, 0.15; 95% CI, 0.06‑0.38; P<0.001) or stable disease (HR, 0.28; 95% CI, 0.13‑0.64; P=0.002), and a subsequent line of treatment upon progression (HR, 0.28; 95% CI, 0.15‑0.52; P<0.001). In the PFE group, 15.4% of patients had a grade >2 infusion reaction to cetuximab and 27.3% had grade 3 skin rash. There were no differences in diarrhoea, hypomagnesaemia, infections and febrile neutropenia; however, the mortality on active treatment was high (13.4%). In conclusion, patients treated with PFE had similar PFS, but improved OS compared with patients treated with the PF protocol. The proportion of patients who died under treatment due to disease progression and toxicity was high in both treatment arms. A thorough selection of patients for this treatment is crucial.

View Figures

View References

1	Cancer in Slovenia 2016. Available from: https://www.onko-i.si/fileadmin/onko/datoteke/dokumenti/RRS/LP_2016.pdf.
2	Argiris A, Harrington KJ, Tahara M, Schulten J, Chromette P, Ferreira Castro A and Licitra L: Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Front Oncol. 7(72)2017.PubMed/NCBI View Article : Google Scholar
3	Vermorken J, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 339:1116–1127. 2008.PubMed/NCBI View Article : Google Scholar
4	Price KA and Cohen EE: Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol. 13:35–46. 2012.PubMed/NCBI View Article : Google Scholar
5	Gatta G, Botta L, Sánchez MJ, Anderson LA, Pierannunzio D and Licitra L: EUROCARE Working Group. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. Eur J Cancer. 51:2130–2143. 2015.PubMed/NCBI View Article : Google Scholar
6	Gregoire V, Lefebvre JL, Licitra L and Felip E: EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21 (Suppl 5):v184–v186. 2010.PubMed/NCBI View Article : Google Scholar
7	Strojan P, Zakotnik B, Žumer B, Karner K, Dremelj M, Jančar B, Jereb S and Grašič Kuhar C: Skin reaction to cetuximab as a criterion for treatment selection in head and neck cancer. Anticancer Res. 38:4213–4220. 2018.PubMed/NCBI View Article : Google Scholar
8	The RECIST Working Group. RECIST 1.1. Available from: https://project.eortc.org/recist/wp-content/uploads/sites/4/2015/03/RECISTGuidelines.pdf.
9	US Department of Health and Human Services: Common Terminology Criteria for Adverse Events. Version 5.0. Published November 27, 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf. Accessed December 12, 2020.
10	Depenni R, Cossu Rocca M, Ferrari D, Azzarello G, Baldessari C, Alu M, Nole F, Codeca C, Boscolo G, Piccininni M, et al: Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting. Eur J Cancer. 115:4–12. 2019.PubMed/NCBI View Article : Google Scholar
11	Magnes T, Melchardt T, Weiss L, Mittermair C, Neureiter D, Klieser E, Gampenrieder S, Moser G, Gaggl A, Griel R and Egle A: Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy. PLoS One. 12(e180995)2017.PubMed/NCBI View Article : Google Scholar
12	Sano D, Fujisawa T, Tokuhisa M, Shimizu M, Sakagami T, Hatano T, Nishimura G, Ichikawa Y, Iwai H and Oridate N: Real-world treatment outcomes of the EXTREME regimen as first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck: A multi-center retrospective cohort study in Japan. Anticancer Res. 39:6819–6827. 2019.PubMed/NCBI View Article : Google Scholar
13	Le Tourneau C, Ghiani M, Cau MC, Depenni R, Ronzino G, Bonomo P, Montesarchio V, Leo L, Schulten J, Messinger D, et al: Cetuximab plus platinum-based therapy (PBT) as a first-line treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): An observational study (ENCORE). Ann Oncol. 29 (Suppl 8):viii372–viii399. 2018.
14	Grünwald V, Chirovsky D, Cheung WY, Bertolini F, Ahn MJ, Yang MH, Castro G, Berrocal A, Sjoquist K, Kuyas H, et al: Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study. Oral Oncol. 102(104526)2020.PubMed/NCBI View Article : Google Scholar
15	Vermorken JB and Specenier P: Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 21 (Suppl 7):S252–S261. 2010.PubMed/NCBI View Article : Google Scholar
16	Argiris A, Li Y and Forastiere A: Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer. 101:2222–2229. 2004.PubMed/NCBI View Article : Google Scholar
17	Anderson JR, Cain KC and Gelber RD: Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 26:3913–3915. 2008.PubMed/NCBI View Article : Google Scholar
18	Alshadwi A, Nadershah M, Carlson ER, Young LS, Burke PA and Daley BJ: Nutritional considerations for head and neck cancer patients: A review of the literature. J Oral Maxillofac Surg. 71:1853–1860. 2013.PubMed/NCBI View Article : Google Scholar
19	Greenlee H, Unger JM, LeBlanc M, Ramsey S and Hershman DL: Association between body mass index (BMI) and cancer survival in a pooled analysis of 22 clinical trials. Cancer Epidemiol Biomarkers Prev. 26:21–29. 2017.PubMed/NCBI View Article : Google Scholar
20	Gama RR, Song Y, Zhang Q, Brown MC, Wang J, Habbous S, Tong L, Huang SH, O'Sullivan B, Waldron J, et al: Body mass index and prognosis in patients with head and neck cancer. Head Neck. 39:1226–1233. 2017.PubMed/NCBI View Article : Google Scholar
21	Guigay J, Feyette J, Dillies AF, Sire C, Kerger JN, Tennevet I, Machiels JP, Zanetta S, Pointreau Y, Bozec Le Moal L, et al: Cetuximab, docetaxel and cisplatin in first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: A multicenter, phase II GORTEC study. Ann Oncol. 26:1941–1947. 2015.PubMed/NCBI View Article : Google Scholar
22	Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, García-Sáenz JA and Cruz-Hernandez JJ: Spanish Head and Neck Cancer Cooperative Group (TTCC). Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent an/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 23:1016–1022. 2012.PubMed/NCBI View Article : Google Scholar
23	Cramer JD, Burtness B and Ferris RL: Immunotherapy for head and neck cancer: Recent advances and future directions. Oral Oncol. 99(104460)2019.PubMed/NCBI View Article : Google Scholar
24	Machiels JP, Rene Leemans C, Golunski W, Grau C, Licitra L and Gregoire C: EHNS Executive Board. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 31:1462–1475. 2020.PubMed/NCBI View Article : Google Scholar
25	Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Baste N, Prakash N, Bratland A, et al: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet. 394:1915–1928. 2019.PubMed/NCBI View Article : Google Scholar